Monnereau Claire, Bruinsma Marieke, Ham Lisanne, Baydoun Lamis, Oellerich Silke, Melles Gerrit R J
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, Netherlands; Melles Cornea Clinic Rotterdam, Rotterdam, Netherlands.
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, Netherlands; Melles Cornea Clinic Rotterdam, Rotterdam, Netherlands; Amnitrans EyeBank Rotterdam, Rotterdam, Netherlands.
Am J Ophthalmol. 2014 Sep;158(3):485-95. doi: 10.1016/j.ajo.2014.05.030. Epub 2014 May 28.
To report early, specific changes in donor endothelial cell morphology as a predictor of an upcoming allograft rejection after Descemet membrane endothelial keratoplasty (DMEK).
Retrospective, observational case series.
Out of a cohort of 500 eyes that underwent DMEK at a tertiary referral center, 7 eyes developed typical clinical signs of an allograft rejection. Specular microscopy images before, during, and after the rejection episode were analyzed and compared with a case-control group of 49 asymptomatic DMEK eyes that matched baseline characteristics of the rejection group. Endothelial cell morphology was evaluated by subjective scoring (range 1-5) in a masked fashion as well as by an objective comparison of endothelial cell density, cell size, coefficient of variation, and hexagonality in rejection vs control eyes.
Subjective scores (median) were higher before and after rejection (2.5 and 5, respectively) than in the DMEK control group (2.0 and 2.5, respectively) at comparable time points (P = .0230 and P = .0005, respectively). Endothelial cell density also differed before (P = .0106) and after rejection (P = .0240), while hexagonality differed before (P = .0499) but not after rejection (P = .1767).
Our study suggests that allograft rejection may not be an acute event, but rather a slow-onset immune response. Early, specific changes in endothelial cell morphology were found to "announce" an upcoming allograft rejection. If so, monitoring donor endothelium after DMEK or other forms of keratoplasty may be used to anticipate a rejection episode and/or to prevent an allograft rejection from clinically manifesting itself.
报告供体内皮细胞形态的早期、特异性变化,作为Descemet膜内皮角膜移植术(DMEK)后即将发生同种异体移植排斥反应的预测指标。
回顾性观察病例系列。
在一家三级转诊中心接受DMEK手术的500只眼中,有7只出现了同种异体移植排斥反应的典型临床症状。分析并比较了排斥反应发作前、发作期间和发作后的镜面显微镜图像,并与49只无症状DMEK眼的病例对照组进行比较,该对照组与排斥反应组的基线特征相匹配。以内盲法通过主观评分(范围1-5)以及通过客观比较排斥反应组与对照组眼中的内皮细胞密度、细胞大小、变异系数和六边形度来评估内皮细胞形态。
在可比时间点,主观评分(中位数)在排斥反应前和排斥反应后(分别为2.5和5)高于DMEK对照组(分别为2.0和2.5)(P分别为0.0230和0.0005)。内皮细胞密度在排斥反应前(P = 0.0106)和排斥反应后(P = 0.0240)也存在差异,而六边形度在排斥反应前(P = 0.0499)存在差异,但在排斥反应后(P = 0.1767)不存在差异。
我们的研究表明,同种异体移植排斥反应可能不是急性事件,而是一种缓慢发生的免疫反应。发现内皮细胞形态的早期、特异性变化可“预告”即将发生的同种异体移植排斥反应。如果是这样,DMEK或其他形式的角膜移植术后监测供体内皮可能用于预测排斥反应发作和/或防止同种异体移植排斥反应在临床上显现出来。